1072902-84-1

Usage

Uses

1. Used in Pharmaceutical Synthesis:
(3S,4S)-3-Hexyl-4[(S)-2-(triisopropylsilyloxy)tridecyl]-2-oxetanone is used as a reagent for the synthesis of enzymatic endocannabinoid 2-arachidonoylglycerol (2-AG) hydrolysis inhibitors and their respective analogs. These inhibitors play a crucial role in modulating the endocannabinoid system, which is involved in various physiological processes, including pain, mood, and appetite regulation. The compound's unique structure allows it to be a valuable building block in the development of novel therapeutic agents targeting the endocannabinoid system.
2. Used in Chemical Research:
As a colorless oil, (3S,4S)-3-Hexyl-4[(S)-2-(triisopropylsilyloxy)tridecyl]-2-oxetanone can be utilized in various chemical research applications, such as studying its reactivity, stability, and potential interactions with other molecules. This may lead to the discovery of new chemical reactions or the development of new synthetic methods.
3. Used in Material Science:
The compound's liquid state and unique molecular structure may also make it a candidate for use in material science, where it could be explored for potential applications in the development of new materials with specific properties, such as improved solubility, reactivity, or stability.

Upstream product

• 1072902-82-9 (2S,3S,5S)-2-hexyl-5-hydroxy-3-[(triisopropylsilyl)oxy]hexadecanoic acid phenylmethyl ester 
• 104872-04-0 Orlistat 
• 130793-30-5 (2S,3S,5S)-2-Hexyl-3,5-dihydroxyhexadecanoic Acid 
• 1072902-83-0 (2S,3S,5S)-2-hexyl-3-hydroxy-5-((triisopropylsilyl)oxy)hexadecanoic acid 

Downstream Products

• 104871-99-0 (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one 
• 1072902-89-6 N-[(phenylmethoxy)carbonyl]-L-proline-(1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester 
• 1310352-51-2 (S)-1-((2S,3S)-3-hexyl-4-oxooxetan-2-yl)tridecan-2-yl 4-fluorobenzoate 
• 1310352-62-5 C₃₅H₅₅NO₆ 

Relevant academic research and scientific papers

One-step modification to identify dual-inhibitors targeting both pancreatic triglyceride lipase and Niemann-Pick C1-like 1

Pancreatic triglyceride lipase (PTL) and Niemann-Pick C1-like 1 (NPC1L1) have been identified as attractive therapeutic targets for obesity and hypercholesteremia, respectively. Obesity and hypercholesteremia usually co-exist, however no dual-inhibitors against PTL and NPC1L1 were reported for the treatment of obesity patients with hypercholesteremia so far. In this work, molecular hybridization-based one-step modification screening identified a potent dual-inhibitor against PTL and NPC1L1. Compound P1-11 has IC50 values of 2.1 μM against PTL through covalent binding, as well as significantly reduces cholesterol absorption in a non-competitive inhibitory manner. Molecule docking and molecular dynamics studies revealed the reason of its activity to both PTL and NPC1L1. Moreover, the gene and protein expression levels of PTL and NPC1L1 were also determined respectively after the treatment of P1-11. Development of dual-inhibitors against PTL and NPC1L1 could provide novel treatment options for obesity patients with hypercholesteremia. The results of current research would great support the development of dual-inhibitors against PTL and NPC1L1.

Orlistat derivatives

The invention relates to orlistat derivatives. In particular, the invention relates to the general formula (I) compound of formula, wherein R such as specification and defined in the claims. The general formula (I) indicated by the compounds can be used as anti-tumor and inhibit lipase activity of the drug.

Inhibitors of an essential mycobacterial cell wall lipase (Rv3802c) as tuberculosis drug leads

The first targeted inhibitors of an essential M. tuberculosis cell wall lipase, Rv3802c, are described. Lead compounds exhibited nanomolar inhibition of the enzyme, and encouraging antibacterial activity against M. tuberculosis in vitro, supporting Rv3802c as a novel TB drug target.

Asymmetric synthesis of anti-aldol segments via a nonaldol route: Synthetic applications to statines and (-)-tetrahydrolipstatin

(Chemical Equation Presented) An asymmetric synthesis of anti-aldol segments via a nonaldol route is described. The strategy involves a highly diastereoselective synthesis of functionalized tetrahydrofuran derivatives from optically active 4-phenylbutyrolactone. Treatment of the tetrahydrofuran derivatives with a Lewis acid and acetic anhydride provided the corresponding ring-opened styrene derivatives. Oxidative cleavage of the styrene derivatives provided access to the anti-aldol segments. The utility of this methodology was demonstrated by the synthesis of statine derivatives and pancreatic lipase inhibitor, (-)-tetrahydrolipstatin.

Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism

A series of 21 analogues of tetrahydrolipstatin (THL, 1) were synthesized and tested as inhibitors of the formation or hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG). Three of the novel compounds, i.e., 11, 13, and 15, inhibited 2-AG formation via the diacylglycerol lipase α (DAGLα) with IC50 values lower than 50 nM (IC50 of THL = 1 μM) and were between 23- and 375-fold selective vs 2-AG hydrolysis by monoacylglycerol lipase (MAGL) as well as vs cannabinoid CB1 and CB2 receptors and anandamide hydrolysis by fatty acid amide hydrolase (FAAH). Three other THL analogues, i.e., 14, 16, and 18, were slightly more potent than THL against DAGLα and appreciably selective vs MAGL, CB receptors, and FAAH (15-26-fold). One compound, i.e., 8, was a potent inhibitor of MAGL-like activity (IC50 = 0.41 μM), and relatively (～7-fold) selective vs the other targets tested.